This record was last updated November 19, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-07-21; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting2025-02-28
Status change: Not Yet Recruiting → Recruiting2022-04-26